AB or CNS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two stocks presents investors with the better value opportunity right now?
Cohen & Steers Portfolio Of CEFs For Income
This analysis reviews Cohen & Steers' nine closed-end funds, focused on income. Fund themes include real estate, preferred securities, infrastructure, utilities, and fixed income. A balanced approach leads to risk reduction, hedging against macroeconomic volatility, ensuring stable income.
Cohen & Steers, Inc. (CNS) Q1 2025 Earnings Call Transcript
Cohen & Steers, Inc. (NYSE:CNS ) Q1 2025 Results Conference Call April 17, 2025 10:00 AM ET Company Participants Brian Heller - Senior Vice President & Deputy Corporate Counsel Raja Dakkuri - Chief Financial Officer John Cheigh - President & Chief Investment Officer Joe Harvey - Chief Executive Officer Conference Call Participants John Dunn - Evercore ISI Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers First Quarter 2025 Earnings Conference Call.
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
Trumpflation Positions Cohen & Steers Poorly Due To Real Estate And Preferred Focus
Cohen & Steers (CNS) faces AUM declines due to asset depreciation in REITs and preferred shares amid persistent inflation affecting bond markets. This could be a portent for incoming outflows or inflow deceleration. At any rate, the macro changes don't favour long-duration asset ETFs that CNS focuses on. Despite positive net inflows, revenue growth was offset by rising expenses, resulting in flat EPS.
Cohen & Steers, Inc. (CNS) Q4 2024 Earnings Call Transcript
Cohen & Steers, Inc. (NYSE:CNS ) Q4 2024 Earnings Conference Call January 23, 2025 10:00 AM ET Company Participants Brian Heller - Senior Vice President & Deputy Corporate Counsel Raja Dakkuri - Chief Financial Officer Joe Harvey - Chief Executive Officer Jeff Palma - Head of our Multi-Asset Solutions Conference Call Participants John Dunn - Evercore ISI Ben Rubin - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers Fourth Quarter and Full Year 2024 Earnings Conference Call.
Corero Network Security to Present at Microcap Conference
MARLBOROUGH, MA / ACCESSWIRE / December 12, 2024 / Corero Network Security (LSE:CNS)(OTCQX:DDOSF), the distributed denial of service (DDOS) protection specialists is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof.
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population.
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM study Quarter marked by pipeline expansion with in-license of TPI 287, a late stage novel potential blood brain barrier permeable abeotaxane for treatment of brain malignancies HOUSTON, TX / ACCESSWIRE / November 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter 2024 ended September 30, 2024. "Our team has made nothing short of transformational advancements throughout 2024.
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.
